Tuesday, 31 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 31 March 2026
News

Companies on a buying blitz

Posted 31 March 2026 AM

Big pharmaceutical companies have dropped a combined $17.6 billion (US$12.1 billion) in the past week in acquisitions, looking to strengthen their portfolios with potential best-in-class compounds.

MSD dropped $9.75 billion (US$6.7 billion) to buy Terns Pharmaceuticals, attracted by a potential best-in-class treatment for myeloid leukemia. The company comes with around US$1 billion in cash, but the price still represents a premium of around 31 per cent to the 60-day average stock price. The deal is expected to close in the second quarter of this year.

To see the whole article, please login

Popular

Butler feels chill from big pharma
PBAC fails the pub test on women
Tough times? Not for pharma's Rich Listers
New approval breaks 30yr drought
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home